慢性呼吸道疾病相关疫苗研发进展

doi:10.19586/j.2095-2341.2025.0003

生物技术进展 ›› 2025, Vol. 15 ›› Issue (3): 396-403.DOI: 10.19586/j.2095-2341.2025.0003

慢性呼吸道疾病相关疫苗研发进展

刘艳花(), 郭蕊, 李岩异, 陈金利()

华北制药金坦生物技术股份有限公司，石家庄 050035

收稿日期:2025-01-06 接受日期:2025-03-26 出版日期:2025-05-25 发布日期:2025-07-01
通讯作者: 陈金利
作者简介:刘艳花 E-mail:395375685@qq.com；

Progress on the Development of Vaccines Related to Chronic Respiratory Diseases

Yanhua LIU(), Rui GUO, Yanyi LI, Jinli CHEN()

North China Pharmaceutical Genetech Biotechnology Co. ，Ltd. ，Shijiazhuang 050035，China

Received:2025-01-06 Accepted:2025-03-26 Online:2025-05-25 Published:2025-07-01
Contact: Jinli CHEN

摘要/Abstract

摘要：

慢性呼吸道疾病（chronic respiratory diseases，CRD）是导致全球每年逾400万人死亡的主要原因。尽管现有治疗方法有助于控制CRD患者日常症状并提高生活质量，但预防由呼吸道感染引发的急性加重仍是治疗的关键。因此，CRD患者是感染性疾病疫苗接种的主要对象。针对CRD患者特定疫苗的最新技术，介绍了呼吸道合胞病毒疫苗、严重急性呼吸综合征冠状病毒2型（severe acute respiratory syndrome cornonavius 2，SARS-CoV-2）疫苗、肺炎球菌疫苗、流感疫苗、百日咳疫苗等最新研发进展，以期为慢性呼吸道疾病预防策略提供参考。

关键词: 慢性呼吸道疾病, 流感, 百日咳, 肺炎球菌疾病疫苗, 呼吸道合胞病毒, SARSCoV-2

Abstract:

Chronic respiratory diseases （CRD） are the leading cause of death for over 4 million people each year worldwide. Although current treatments help manage daily symptoms and improve patients' quality of life， the acute exacerbations primarily triggered by respiratory infections still need prevention. Therefore， CRD patients are the main target of vaccination against infectious diseases. In this article， we reviewed the latest technologies available for vaccines specifically indicated for CRD patients， including respiratory syncytial virus vaccines， SARS-CoV-2 vaccines for pneumococcal infections， influenza， pertussis vaccines， and more， which was expected to provide reference for the prevention strategies for chronic respiratory diseases.

Key words: chronic respiratory diseases, influenza, pertussis, pneumococcal disease vaccine, respiratory syncytial virus, SARS-CoV-2

中图分类号:

Q189

刘艳花, 郭蕊, 李岩异, 陈金利. 慢性呼吸道疾病相关疫苗研发进展[J]. 生物技术进展, 2025, 15(3): 396-403.

Yanhua LIU, Rui GUO, Yanyi LI, Jinli CHEN. Progress on the Development of Vaccines Related to Chronic Respiratory Diseases[J]. Current Biotechnology, 2025, 15(3): 396-403.

图/表 1

参考文献 24

1	ZHANG D, ZHENG J. The burden of childhood asthma by age group, 1990-2019: a systematic analysis of global burden of disease 2019 data[J/OL]. Front. Pediatr., 2022, 10: 823399[2025-04-01]. .
2	VINIOL C, VOGELMEIER C F. Exacerbations of COPD[J/OL]. Eur. Respir. Rev., 2018, 27(147): 170103[2025-05-20]. .
3	CABLE J, SUN J, CHEON I S, et al.. Respiratory viruses: new frontiers a keystone Symposia report[J]. Ann. NY Acad. Sci., 2023, 1522(1): 60-73.
4	SIM Y S, LEE J H, LEE E G, et al.. COPD exacerbation-related pathogens and previous COPD treatment[J/OL]. J. Clin. Med., 2022, 12(1): 111[2025-04-01]. .
5	BINNS E, TUCKERMAN J, LICCIARDI P V, et al.. Respiratory syncytial virus, recurrent wheeze and asthma: a narrative review of pathophysiology, prevention and future directions[J]. J. Paediatr. Child Health, 2022, 58(10): 1741-1746.
6	HEPPE-MONTERO M, GIL-PRIETO R, DEL DIEGO SALAS J, et al.. Impact of respiratory syncytial virus and influenza virus infection in the adult population in Spain between 2012 and 2020[J/OL]. Int. J. Environ. Res. Public Health, 2022, 19(22): 14680[2025-04-01]. .
7	KAMPMANN B, MADHI S A, MUNJAL I, et al.. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants[J]. N. Engl. J. Med., 2023, 388(16): 1451-1464.
8	MOSMANN T R, MCMICHAEL A J, LEVERT A, et al.. Opportunities and challenges for T cell-based influenza vaccines[J]. Nat. Rev. Immunol., 2024, 24(10): 736-752.
9	PARDI N, KRAMMER F. mRNA vaccines for infectious diseases-advances, challenges and opportunities[J]. Nat. Rev. Drug Discov., 2024, 23(11): 838-861.
10	JACKSON L A, ANDERSON E J, ROUPHAEL N G, et al.. An mRNA vaccine against SARS-CoV-2-preliminary report[J]. N. Engl. J. Med., 2020, 383(20): 1920-1931.
11	MCLELLAN J S, CHEN M, JOYCE M G, et al.. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus[J]. Science, 2013, 342(6158): 592-598.
12	GRAHAM B S. Immunological goals for respiratory syncytial virus vaccine development[J]. Curr. Opin. Immunol., 2019, 59: 57-64.
13	WILSON E, GOSWAMI J, BAQUI A H, et al.. Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults[J]. N. Engl. J. Med., 2023, 389(24): 2233-2244.
14	HAMMITT L L, DAGAN R, YUAN Y, et al.. Nirsevimab for prevention of RSV in healthy late-preterm and term infants[J]. N. Engl. J. Med., 2022, 386(9): 837-846.
15	YIN T, LI Y, YING Y, et al.. Prevalence of comorbidity in Chinese patients with COVID-19: systematic review and meta-analysis of risk factors[J/OL]. BMC Infect. Dis., 2021, 21(1): 200[2025-04-01]. .
16	LIU S, CAO Y, DU T, et al.. Prevalence of comorbid asthma and related outcomes in COVID-19: a systematic review and meta-analysis[J]. J. Allergy Clin. Immunol. Pract., 2021, 9(2): 693-701.
17	BLOOM C I, DRAKE T M, DOCHERTY A B, et al.. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO clinical characterisation protocol UK[J]. Lancet Respir. Med., 2021, 9(7): 699-711.
18	LI Y, ZHANG P, AN Z, et al.. Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations[J]. Respirology, 2022, 27(10): 844-853.
19	BIANCARDI E, FENNELL M, RAWLINSON W, et al.. Viruses are frequently present as the infecting agent in acute exacerbations of chronic obstructive pulmonary disease in patients presenting to hospital[J]. Intern. Med. J., 2016, 46(10): 1160-1165.
20	BLASI F, BONANNI P, BRAIDO F, et al.. The unmet need for pertussis prevention in patients with chronic obstructive pulmonary disease in the Italian context[J]. Hum. Vaccin. Immunother., 2020, 16(2): 340-348.
21	CAMPLING J, VYSE A, LIU H H, et al.. A review of evidence for pneumococcal vaccination in adults at increased risk of pneumococcal disease: risk group definitions and optimization of vaccination coverage in the United Kingdom[J]. Expert Rev. Vaccines, 2023, 22(1): 785-800.
22	TALBOT T R, HARTERT T V, MITCHEL E, et al.. Asthma as a risk factor for invasive pneumococcal disease[J]. N. Engl. J. Med., 2005, 352(20): 2082-2090.
23	BEHRENS C, AGARWAL F J, ARULKUMAR P, et al.. Development of a next generation 30+valent pneumococcal conjugate vaccine (VAX-XP) using site-specific carrier protein conjugation[J/OL]. Open ForumInfect Dis., 2021, 8(S1): 615[2025-04-14]. .
24	FEREDJ E, WIEDEMANN A, KRIEF C, et al.. Immune response to pertussis vaccine in COPD patients[J/OL]. Sci. Rep., 2023, 13(1): 11654[2025-04-01]. .

药品名称	技术类型	研发公司	上市日期	信息来源
Arexvy	重组蛋白疫苗	英国葛兰素史克（GSK）	2023年5月（FDA批准）	https://www.fda.gov/vaccines-blood-biologics/arexvy
Abrysvo	重组蛋白疫苗	美国辉瑞（Pfizer）	2023年5月（FDA批准）	https://www.fda.gov/vaccines-blood-biologics/abrysvo
mRNA-1345	mRNA疫苗	美国莫德纳（Moderna）	2024年6月（FDA批准）	https://www.‍fda.‍gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine

药品名称	技术类型	研发公司	上市日期	信息来源
Arexvy	重组蛋白疫苗	英国葛兰素史克（GSK）	2023年5月（FDA批准）	https://www.fda.gov/vaccines-blood-biologics/arexvy
Abrysvo	重组蛋白疫苗	美国辉瑞（Pfizer）	2023年5月（FDA批准）	https://www.fda.gov/vaccines-blood-biologics/abrysvo
mRNA-1345	mRNA疫苗	美国莫德纳（Moderna）	2024年6月（FDA批准）	https://www.‍fda.‍gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine

[1]	吕娜, 李岩异, 马祝青. 人呼吸道合胞病毒感染的预防和治疗研究进展[J]. 生物技术进展, 2024, 14(1): 26-34.
[2]	杨高松,马东杰. 呼吸道传染病治疗中抗体药物的研发进展[J]. 生物技术进展, 2020, 10(5): 441-447.

慢性呼吸道疾病相关疫苗研发进展

Progress on the Development of Vaccines Related to Chronic Respiratory Diseases

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 24

相关文章 2

编辑推荐

Metrics

本文评价